

Harris & Harris Group, Inc.®



**Transformative Companies
Enabled by Nanotechnology**

SAFE HARBOR STATEMENT



This presentation may contain statements of a forward-looking nature relating to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.

Please see the Company's Annual Report on Form 10-K, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

INVESTING EXCLUSIVELY IN NANOTECHNOLOGY SINCE 2002



WE HAVE A PIPELINE OF PORTFOLIO COMPANIES



	Cleantech	Healthcare	Electronics
Early Stage	Laser Light Engines Produced Water Absorbents Nextreme Ultora	Ancora Enumeral	
Mid Stage	Cobalt Contour Energy ABSMaterials	Mersana Ensemble Champions Oncology	Adesto SiOnyx D-Wave Systems Nantero Cambrios Kovio
Late Stage	Solazyme (NASDAQ:SZYM) Bridgelux Innovalight ⁽¹⁾ Nanosys	Metabolon	Xradia NeoPhotonics (NYSE:NPTN) Molecular Imprints
Realized Positive Exits	Siluria	NanoGram Devices BioVex ⁽²⁾	

Note: Portfolio companies and stage classifications as of June 30, 2011. Table does not include portfolio companies valued at \$0 as of June 30, 2011.

- (1) Innovalight was acquired by DuPont on July 21, 2011
- (2) A portion of the potential amount we will receive from the sale of BioVex remains unrealized as of June 30, 2011.

OUR PARTNERS



> \$1 billion in capital from other venture capital firms

Over two thirds have significant corporate partnerships or investors

Over \$80 million in federal funding

\$126 million Invested by H&H

Leverage on Our Investments



Note: All numbers are as of March 31, 2011.

WE WERE EARLY INVESTORS IN TODAY'S GROWTH MARKETS





Healthcare

Cancer Therapeutics – Biologics




2001 2002 2003 2004 2005 2006 2007 2008 2009 2010



Disease free at 4 years

TRENDS IN NANOMEDICINE



1. 3D Biology

- Limitations of 2D models for drug development.

2. Molecular Engineering

- Engineering proteins and small molecules to enable new classes of compounds.

3. Personalized Medicine

- Trends in molecular diagnostics.

4. Cellular Therapy

- Trends in stem cell therapy.

OUR HEALTHCARE PORTFOLIO



Acquired by Amgen: up to \$1 billion



METABOLON

ENSEMBLE | DISCOVERY



